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Abstract: The impact of the mitochondria-targeted antioxidant MitoQ was evaluated in the cardiac
alterations associated with obesity. Male Wistar rats were fed either a high fat diet (HFD, 35% fat) or a
standard diet (CT, 3.5% fat) for 7 weeks and treated with MitoQ (200 µM). The effect of MitoQ (5 nM) in
rat cardiac myoblasts treated for 24 h with palmitic acid (PA, 200 µM) was evaluated. MitoQ reduced
cardiac oxidative stress and prevented the development of cardiac fibrosis, hypertrophy, myocardial
18-FDG uptake reduction, and mitochondrial lipid remodeling in HFD rats. It also ameliorated cardiac
mitochondrial protein level changes observed in HFD: reductions in fumarate hydratase, complex
I and II, as well as increases in mitofusin 1 (MFN1), peroxisome proliferator-activated receptor
gamma coactivator 1-alpha, and cyclophilin F (cycloF). In vitro, MitoQ prevented oxidative stress and
ameliorated alterations in mitochondrial proteins observed in palmitic acid (PA)-stimulated cardiac
myoblasts: increases in carnitine palmitoyltransferase 1A, cycloF, and cytochrome C. PA induced
phosphorylation of extracellular signal-regulated kinases and nuclear factor-κB p65. Therefore, the
data show the beneficial effects of MitoQ in the cardiac damage induced by obesity and suggests a
crosstalk between lipotoxicity and mitochondrial oxidative stress in this damage
Keywords: cardiac fibrosis; cardiac hypertrophy; cardiac lipotoxicity; mitochondrial function; obesity;
oxidative stress
1. Introduction
Obesity, which is characterized by excessive accumulation of adipose tissue and lipids, forming
ectopic fat deposits in different tissues including the heart [1,2], is associated with a higher risk of
cardiovascular morbidity and mortality [3,4]. This cardiac lipotoxicity can trigger cellular alterations,
since the exposure of the heart to elevated plasma levels of free fatty acids (FFAs) may cause
accumulation of toxic lipid intermediates within cardiomyocytes [1,5]. In addition, lipids are essential
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regulators of cardiac function through their role in signaling, membrane structure, and transport, and
as substrate for β-oxidation in the mitochondria [1,6,7]. Although fatty acid β-oxidation is the main
energy source, the heart also obtains energy from glucose and/or lactate depending upon substrate
availability. However, during obesity, the heart is characterized by a decrease in glucose utilization due
to an excess of fatty acids (FA). This shift could reduce cardiac efficiency since FA oxidation consumes
more oxygen per ATP molecule produced than glucose [8], and affects mitochondrial function. The
altered insulin signaling of the obese heart is considered an adaptation to a calorie overabundance [9].
The heart demands an elevated quantity of energy being supported by a highly active mitochondrial
system. Mitochondria comprise almost a third of cardiomyocyte volume, are the source of ATP, and
play a central role in the calcium homeostasis necessary for maintaining cardiomyocyte viability
and contractility. Mitochondria are also the main source of reactive oxygen species (ROS), which
can be exacerbated in different pathological conditions, including obesity [10,11]. Dysregulation of
mitochondrial function in the context of obesity can participate not only in the cardiac consequences of
obesity, but as well as in its metabolic ones, since the administration of a mitochondrial antioxidant
was able to improve cardiac damage and improve insulin resistance in adipose tissue associated with
obesity [10,12–14]. Although the potential role of cardiolipotoxicity and mitochondrial oxidative stress
in the cardiac damage associated with obesity is accepted, how these two mechanisms interact in
this damage remains unclear. Therefore, our aim has been to characterize the interactions between
cardiolipotoxicity and mitochondrial oxidative stress in the cardiac alterations in diet-induced obese
rats. To address this aim, we evaluated the impact of mitochondrial lipid profile, in cardiac fibrosis
and hypertrophy, as well as the cardiac metabolic alterations in obese rats. In addition, the effect of the
mitochondrial-targeted antioxidant MitoQ on these changes and their consequences on mitochondrial
proteins has been evaluated. We have also analyzed the effect of palmitic acid (PA) on mitochondrial
oxidative stress and mitochondrial proteins in cultured cardiac myoblasts.
2. Material and Methods
2.1. Animal Model
Male Wistar rats of 150 g (Envigo, Barcelona, Spain) were fed either a high fat diet (HFD, 35%
fat; Envigo Teklad no. TD.03307, Haslett, MI, USA; n = 16) or a standard diet (CT, 3.5% fat; Envigo
Teklad no.TD.2014, Haslett, MI, USA; n = 16) for 7 weeks. Half of the animals of each group received
the mitochondrial antioxidant MitoQ (200 µM) in the drinking water for the same period. The dose of
MitoQ was based on previous data [15]. MitoQ was provided by MP Murphy from Medical Research
Council Mitochondrial Biology Unit, Cambridge BioMedical Campus, Cambridge, UK. Body weight
was measured once per week. Systolic blood pressure (SBP) was estimated end-of-study through use
of a tail-cuff plethysmograph (Narco Bio-Systems) in unrestrained rats. The Animal Care and Use
Committee of Universidad Complutense de Madrid approved all experimental procedures according
to the Spanish Policy for Animal Protection RD53/2013, which meets the European Union Directive
2010/63/UE. At the end of the experiment, serum and plasma were collected.
2.2. Evaluation of Cardiac Structure and Function
2.2.1. Echocardiographic Study
Cardiac function was evaluated by transthoracic echocardiography with an Acuson Sequoia 256
(Siemens Medical Solutions, Germany) connected to a 15-MHz linear transducer. The 2D-guided
M-mode recordings were made from short-axis views to measure left ventricular (LV) chamber
dimensions, interventricular septum and posterior wall thickness. LV diastolic (LVDA) and
systolic (LVSA) areas were measured from the bidimentional parasternal long-axis view. The mean
measurements from several consecutive beats were used for data analysis. LV chamber volumes
were calculated using the cylindrical model. This model assumes the ventricle is approximated by a
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cylinder. Left ventricular ejection fraction (EF) was calculated in percentage according to the Teicholz
Formula: (EDD3 × 7)/(2.4 + EDD). Fractional shortening was calculated according to the following
formula: (EDD − EDS)/EDD in percentage. The diastolic function was assessed by early and late
transmitral peak diastolic flow velocity (E and A waves) and ratio between E-waves and A-wave (E/A)
was calculated. The images were processed with the software MASS (Medis Medical Imaging Systems,
Best, Norway).
2.2.2. Morphological and Histological Evaluation
Cardiac tissue samples were dehydrated, embedded in paraffin, and cut in 4 µm-thick sections.
Sections were stained with picrosirius red in order to detect collagen fibers, or hematoxylin and eosin
to measure cardiac myocyte area. The area of cardiac interstitial fibrosis was identified as the ratio
of interstitial fibrosis or collagen deposition to the total tissue area after excluding the vessel area
from the region of interest. For each sample, 10 to 15 fields were analyzed with a 40× objective under
transmitted light microscopy (Leica DM 2000; Leica AG, Germany). Myocytes (60–80 per animal) with
visible nucleus and intact cellular membranes were chosen for determination of cross-sectional area
in hematoxylin and eosin staining sections with a 40× objective under transmitted light microscopy
(Leica DM 2000). Quantitative analysis was performed using an analysis system (Leica LAS 4.3).
2.2.3. Isolation of Cardiac Mitochondria
Cardiac mitochondria were isolated as reported [5]. Frozen hearts were placed and washed in
cold homogenization medium containing 0.075 mol/L sucrose, 1 mmol/L EDTA, 10 mmol/L Tris-HCl,
and pH 7.4. Briefly, heart tissue was homogenized (1:10 w/v) at 800br pm in a homogenizer (T 10 basic
Ultra-turrax, Ika-Werke; Germany). The homogenates were centrifuged at 1300× g for 5 min at 4 ◦C
to remove nuclei and debris. Supernatants were separated and centrifuged at 12,000× g for 10 min
at 4 ◦C. The resulting pellets were suspended in homogenization medium and centrifuged twice at
14,400× g for 3 min at 4 ◦C to wash the mitochondrial fraction. Mitochondrial pellets were stored at
−80 ◦C until use. Protein concentration was determined by the Bradford method.
2.2.4. Lipidomic Analysis
Mitochondrial myocardial lipids were extracted and analyzed by ultrahigh performance liquid
chromatography coupled to time-of-flight mass spectroscopy (UPLC-QToF-MS) using an Acquity
UPLC System and a SYNAPT HDMS G2 (Waters, Manchester, UK) with electrospray ionization.
Methanol:chloroform (1:2) cardiac extracts were evaporated to dryness and the pellet resuspended in
250 µL of acetone:2-propanol:ethanol (3:4:3) and used for triglyceride (TG) measurement, as previously
reported [5]. Another aliquot was evaporated to dryness and the pellet resuspended in 200 µL
methanol:water (9:1) and used for phospholipid (PPLs) measurement as previously reported [16].
Extracts were kept at −80 ◦C until analysis.
Using Lipid Maps, Metlin, CheBI, LipidBank, and KEGG databases, a particular elemental
composition was searched for possible known compounds. Where possible, acyl chains were aimed at
being identified by data from the high-energy function (fragmentation). To assess the specific location
of each acyl chain (at the positions sn-1 or sn-2 of the glycerol backbone) is not possible using this
methodology; thus, the most current structure is indicated. The chromatographic peak area from the
extracted ion chromatogram of every m/z value detected, whether or not having been identified, was
quantified using the QuanLynx application.
Chromatograms and mass spectra of all samples were processed with a MarkerLynx method in
order to search for differential features (retention time m/z) amongst sample groups. Five injections of
methanol were used as blanks to determine features prone to rejection. Only features that appeared in
66% of the samples were accepted. Sets of about 1650 features for data in negative mode and about
2109 features for data in positive mode were detected using the MarkerLynx application. They were
checked manually to remove all the features that were present in the blanks. The array resulting
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from this process, which is comprised of samples and features as independent variables, and the
feature signal intensity as dependent variable was submitted to multivariate statistical analysis using
the Extended Statistics application that is available with the instrument software; this application is
licensed from part of the statistical software SIMCA+ from Umetrics Ltd. (Sweden).
2.2.5. In Vivo PET-CT Imaging to Study Uptake of 18F-Fluorodeoxyglucose in the Heart
Myocardial metabolic activity was evaluated by means of a small-animal dedicated dual scanner
(Albira PET/CT scanner, Bruker NMI, Valencia Spain). One week before the end of the experiment,
animals were starved for 18 h, followed by intraperitoneal injection with 18F-fluorodeoxyglucose [FDG;
12.99 ± 0.04 MBq in 0.2 mL NaCl (0.9%); Instituto Tecnológico PET, Madrid, Spain]. Twenty min later,
rats underwent Positron Emission Tomography (PET) and computed tomography (CT) scanning under
isoflurane anesthesia. The acquired PET and CT images were then reconstructed by, respectively,
using maximum-likelihood (ML) expectation-maximization (EM) [ML-EM] and filtered-back projection
algorithms. In order to account for the weight difference in rats and the [18F] doses of injected FDG, we
calculated the standardized uptake value (SUV). The semi-quantitative SUV measurement is the most
widely used in [18F] FDG PET studies of both small animals and humans [17]. The software used was
PMOD 3.6 (PMOD Technologies Ltd., Zurich, Switzerland).
To quantify the metabolic activity, the CT image of the heart from each animal was registered to
its corresponding PET image. Then a three-dimensional region of interest (ROI) was drawn on the
fused PET/CT image to measure the metabolic activity of the entire left ventricle. These steps were
carried out by using PMOD 3.0. SUV was obtained as an index of regional metabolic activity. The SUV
parameter was calculated as a ratio of the ROI radioactivity concentration (kBq/mL) measured by the
scanner, and the administered dose (kBq) was decay-corrected at the time of the injection, divided by
the body weight (g).
2.2.6. Measurement of Cardiac Reactive Oxygen Species (ROS) Production
For detection of either total or mitochondrial superoxide anion (O2−) levels, cardiac sections
(14µm) were incubated with dye dihydroethidium (DHE; 10−5 M) for 30 min or MitoSox (5× 10−6 M) for
10 min, respectively at 37 ◦C. DHE is oxidized by superoxide and exhibits red fluorescence. MitoSOX™
is rapidly and selectively targeted to the mitochondria where it is oxidized by superoxide and exhibits
red fluorescence. The oxidation products become highly fluorescent upon binding to nucleic acids.
Fluorescent signals were viewed using a fluorescent laser scanning microscope (40× objective in Leica
DMI 3000 microscope). Quantitative analysis of O2− production was performed by using an image
analyzer (Leica LAS 4.3; Leica AG, Germany). Three sections per animal were quantified and averaged
for each experimental condition. The mean fluorescence densities in the target region were analyzed.
Results are expressed as n-fold increase over the values of the control group in arbitrary units.
2.2.7. Intracellular Lipid Droplet Evaluation
The lipid content within the cells was assessed by oil red O staining OCT frozen cardiac sections
mounted on 10% glycerol in PBS-DAPI (5 ng/µL) to visualize the nucleus, and stained with Oil red
O. Fluorescent signals were viewed using a fluorescent laser scanning microscope (40× objective in
Leica DMI 3000 microscope). Quantitative analysis of lipid droplet content was performed by using an
image analyzer (LEICA Q550 IWB Leica LAS 4.3; Leica AG, Germany). Three sections per animal were
quantified and averaged for each experimental condition. The mean fluorescence densities in the target
region were analyzed. Results are expressed as the ratio of lipid droplet content to the total tissue area.
2.3. Western Blot Analysis
Total cardiac and cellular proteins were separated by SDS-PAGE on 4–15% polyacrylamide gels
and transferred to Hybond-c Extra nitrocellulose membranes (Hybond-P; Amersham Biosciences,
Piscataway, NJ, USA) with the Trans-Blot Turbo Transfer System. Membranes were probed with
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primary antibody for acetyl CoA synthetase (ACS, Abcam; Cambridge, UK; dilution 1/500), adipose
triglyceride lipase (ATL, Abcam; Cambridge, UK; dilution 1/1000), carnitine palmitoyltransferase 1A
(CPT1A, Abcam; Cambridge, UK; dilution 1/1000), cyclophilin F (cycloF, Santa Cruz Biotechnology;
Dallas, TX, USA; dilution 1/500), cytochrome C (cytoC, Abcam; Cambridge, UK; dilution 1/500),
diacylglycerol O-acyltransferase 1 (DGTA1, Abcam; Cambridge, UK; dilution 1/1000), Dynamin-1-like
protein (DRP1, Abcam; Cambridge, UK; dilution 1/500), extracellular signal-regulated kinases (Erk1/2,
ThermoFisher; Rockford, IL, USA; dilution 1/1000), Erk1/2 (phosphor-p44/42 Thr202/Tyr204, Cell
Signaling, Danvers, MA, USA; dilution 1/1000), fatty acid translocase (FAT; Abcam; Cambridge, UK;
dilution1/1000), fumarate hydratase (FH; Santa Cruz Biotechnology; Dallas, TX, USA; dilution 1/1000),
mitofusin 1 (MFN1, Abcam; Cambridge, UK; dilution 1/1000), nuclear factor-κB p65(NF-κB, Abcam;
Cambridge, UK; dilution 1/1000), NF-κB (phospho S536, Abcam; Cambridge, UK; dilution 1/1000),
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α, Abcam; Cambridge,
UK; dilution 1/1000), protein kinase B (Akt, Cell Signaling, Danvers, MA, USA; dilution 1/1000), Akt,
(phospho Ser473, Cell Signaling, Danvers, MA, USA; dilution 1/1000), 4-hydroxynonenal (4HNE,
Abcam; Cambridge, UK; dilution 1/250) and GAPDH and β-actin (Sigma-Aldrich; dilution 1/5000), as
loading controls. Signals were detected using the ECL system (Amersham Pharmacia Biotech). Results
are expressed as an n-fold increase over the values of the control group in densitometric arbitrary units.
The Mitoprofile Total OXPHOS Rodent WB Antibody Cocktail (Abcam¸ Cambridge, UK; dilution
1/1000) was used to quantify the relative levels of the subunits of the mitochondrial OXPHOS complexes:
NDUFB8 subunit of complex I, SDHB subunit of complex II, core protein 2 UQCRC2 of complex III,
MTCO1 subunit 1 of complex IV, and α-subunit of complex V or ATP synthase. For detection of
OXPHOS subunits, all western blot steps were followed.
2.4. Cell Culture Studies
Cells of the H9c2 rat cardiomyoblast cell line (Merck, Darmstadt, Germany) were maintained
in Dulbecco’s modified Eagle’s medium (DMEM; Merck, Darmstadt, Germany) supplemented with
25 mM glucose, 1 mM pyruvate, and 2 mM L-glutamine. Cells were cultured according to the
manufacturer′s instructions and were used until passages 15–17. For the experiments, cells were
seeded into 6-well plates at 90% confluence, and serum starved for 18 h, and 6 wells were evaluated
for each experimental condition. All assays in the present study were done at a temperature of 37 ◦C,
95% sterile air, and 5% CO2 in a saturation humidified incubator. Cells were stimulated with 200 µM
of PAwith bovine serum albumin (BSA) as a carrier—conjugated to 10% free fatty acids (FFA)-free
BSA for 24 h in the presence or absence of MitoQ (5 nM). In order to evaluate the potential pathways
involved in the effects of PA, cells were stimulated with 200 µM of palmitate–BSA for 5–60 min, and
total and phosphorylated proteins of Akt, Erk, and NF-κB were evaluated.
2.5. Statistical Analysis
Variables are expressed as mean ± SEM. Normality of distributions was verified by means of the
Kolmogorov–Smirnov test. Differences among groups were analyzed using 1-way ANOVA followed
by Newman-Keuls test. Pearson correlation analysis was used to examine association among different
variables according to whether they are normally distributed. A value of p < 0.05 was used as the cutoff
value for defining statistical significance. Data analysis was performed using the statistical program
SPSS version 25.0 (SPSS Inc, Chicago, IL, USA).
3. Results
Animals fed an HFD showed an increase in body weight and adiposity index after seven weeks
of HFD intake when compared to control rats [12]. Obese rats also showed an increase in relative
heart weight, suggesting cardiac hypertrophy, cardiomyocyte area, and cardiac fibrosis, although no
changes in cardiac function or blood pressure were observed (Table 1, Figure 1A,B). Treatment with
MitoQ reduced the changes observed in obese rats, supporting the role of mitochondrial oxidative
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stress in these alterations. MitoQ treatment did not affect any of these parameters in control animals
(Table 1) [12]. Therefore, and to simplify the results, only rats fed a standard diet and HFD treated with
vehicle or MitoQ (HFD + MitoQ) will herein be considered.
Table 1. Effect of the antioxidant mitochondrial MitoQ (200 µM) on relative heart weight, cardiomyocyte
cross-sectional area, echocardiographic parameters, and systolic blood pressure in rats fed a normal
chow (CT) and rats fed a high fat diet (HFD).
CT MitoQ HFD HFD-MitoQ
HW/TL (g/cm) 0.20 ± 0.003 0.21 ± 0.006 0.24 ± 0.007 *** 0.22 ± 0.004 *†
CSA (µm2) 301.2 ± 7.8 308.1 ± 7.7 380.3 ± 11.9 *** 322.7 ± 10.8 †††
IVTs (mm) 0.130 ± 0.008 0.137 ± 0.006 0.143 ± 0.02 0.135 ± 0.008
PWTs (mm) 0.190 ± 0.013 0.140 ± 0.008 0.171 ± 0.012 0.167 ± 0.019
ESD (mm) 0.352 ± 0.034 0.403 ± 0.012 0.293 ± 0.030 0.349 ± 0.032
EDD (mm) 0.653 ± 0.043 0.670 ± 0.022 0.615 ± 0.023 0.613 ± 0.032
EF (%) 77.8 ± 3.7 73.2 ± 2.8 82.3 ± 1.9 77.3 ± 5.3
FS (%) 44.0 ± 3.3 41.4 ± 2.0 49.3 ± 4.7 43.2 ± 4.8
E/A 1.05 ± 0.08 1.20 ± 0.03 1.07 ± 0.05 1.20 ± 0.02
SBP (mmHg) 133.7 ± 2.5 130.6 ± 3.9 138.1 ± 2.1 133.9 ± 2.6
Data values represent mean ± SEM of 8 animals. CSA indicates cardiomyocyte cross-sectional area; EDD,
end-diastolic diameter; EF, ejection fraction; ESD, end-systolic diameter; FS, fractional shortening; HW, heart weight;
IVT, interventricular septum thickness; PWT, posterior wall thickness; SBP, systolic blood pressure; and TL, tibia
length. * p < 0.05, *** p < 0.001 vs. control group and † p < 0.05; ††† p < 0.001 vs. HFD group.
Figure 1. Effects of the mitochondrial antioxidant MitoQ (MQ) on cardiac interstitial fibrosis, superoxide
anion levels and cardiac 18-FDG uptake in obese rats. Hearts from rats fed a standard diet (CT) or
a high fat diet (HFD) treated with vehicle or with MQ (200 µM) were analyzed. (A) Quantification
of collagen volume fraction (CVF) and (B) representative microphotographs of sections stained with
picrosirius red. (C) Quantification of total cardiac levels of superoxide anion and (D) representative
microphotographs of cardiac sections labeled with DHE. (E) Quantification of myocardial 18-FDG uptake
and (F) Representative photographs of 18F-Fluorodeoxyglucose (FDG) PET/CT scans in trans-axial
views scaled to standardized uptake value (SUV). Magnification (×40).Bar graphs represent the mean
± SEM. of 6–8 animals. * p < 0.05; ** p < 0.01; *** p < 0.001 vs. control group. † p < 0.05; †† p < 0.01;
††† p < 0.001 vs. HFD group.
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The efficiency of MitoQ treatment was evaluated by measurement of both total and mitochondrial
cardiac O2− levels. HFD-fed rats showed higher O2− of both total and mitochondrial cardiac levels as
compared with CT animals, as suggested by the higher fluorescence staining observed in the heart of
the obese animals in response to DHE or MitoSox, respectively (Figure 1C,D and Figure S1A,B). These
higher levels were reduced by the MitoQ treatment (Figure 1C,D and Figure S1A,B), supporting the
effectiveness of MitoQ. We then explored whether the increase in oxidative stress can affect myocardial
use of glucose. Representative examples of PET images (Figure 1E,F) revealed that the control group
show more 18-FDG uptake in the hearts as compared with obese animals. The administration of
MitoQ was able to ameliorate myocardial 18-FDG uptake in HFD-fed rats, although it was unable to
normalize it, suggesting the participation of mitochondrial oxidative stress, at least in part, in the
cardiac metabolic alterations observed in obese rats. Similarly, MitoQ was able to reduce the increase
in HOMA index in obese rats [12]. The 18-FDG uptake levels were negatively associated with cardiac
fibrosis and hypertrophy (Table 2).
An increase in lipid content was observed in the heart of obese rats (Figure 2A,B) that was
accompanied by an increase in total mitochondrial triglycerides (TG) content in obese animals
(Figure 2C), mainly due to an accumulation of TGs enriched with PA (C16:0), which account for almost
50% of these (Figure 2D). Treatment with MitoQ was able to reduce this rise observed in animals that
were fed an HFD (Figure 2A–D). Cardiac TG levels were associated with those of 18-FDG uptake,
cardiac fibrosis, and cardiac hypertrophy (Table 2). We explored whether high cardiac mitochondrial
TG levels could be due to an increase in flow into mitochondria. Figure 3A shows an increase in CPT1A
levels in obese rats as compared with controls, which was prevented by MitoQ treatment. A similar
pattern was observed with FAT, a fatty acid protein transport into the cell, since it was increased in
obese animals and reduced in those treated with MitoQ (Figure 3B). The mitochondrial cardiac TG
levels were associated with both CPT1A (r = 0.674; p = 0.001) and FAT (r = 0.588; p = 0.008) levels.
An increase in DGAT1 levels—involved in the last step of TG synthesis—was also observed in HFD
rats and reduced in those treated with MitoQ (Figure 3C). However, no significant differences were
observed among any group in the levels of ATL involved in TG degradation (Figure 3D).
Table 2. Association between cardiac fibrosis, hypertrophy, and 18-FDG uptake, and those of
mitochondrial lipid composition and proteins in the hearts of rats fed either a normal chow (CT) or a
high fat diet (HFD) treated with vehicle or MitoQ (200 µM).
Cardiac Fibrosis Cardiac Hypertrophy 18-FDG Uptake
r p r p r p
Cardiac fibrosis - - 0.792 <0.0001 −0.636 0.003
Cardiac hypertrophy 0.792 <0.0001 - - −0.661 0.002
Mitochondrial TGs 0.586 0.007 0.641 0.003 −0.578 0.01
Mitochondrial FFA 0.759 <0.0001 0.487 0.048 - -
Mitochondrial CL −0.555 0.017 - - - -
Mitochondrial
Ceramides 0.547 0.015 0.624 0.006 −0.460 0.041
MFN1 - - 0.549 0.018 −0.581 0.011
FH −0.564 0.01 −0.469 0.037 −0.596 0.006
CL: cardiolipins, FFA: free fatty acid, FH: fumarate hydratase, MFN1: mitofusin 1; TGs: triglycerides.
Cardiac levels of FFAs were elevated in HFD animals as compared with CT (Figure 4A) mainly
due to an accumulation of those enriched with saturated FFA (C16:0, C18:0) orω-6 FFAs (Figure S2A,B).
No significant changes were observed in the levels of those FFAs enriched with ω-3 among any group.
Consequently, the ratioω-6/ω-3 was increased in obese animals (data not shown). MitoQ treatment
was able to reduce these increases supporting the participation of mitochondrial oxidative stress in
these changes (Figure 4A and Figure S2A,B). Total FFA levels were associated with the levels of those of
either cardiac fibrosis or hypertrophy (Table 2). Cardiolipins (CL) levels were reduced in obese animals
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and normalized in MitoQ-treated rats, supporting the role of mitochondrial oxidative stress in the
upregulation of CL (Figure 4B). These levels were negatively associated with those of fibrosis (Table 2).
Figure 2. Impact of the mitochondrial antioxidant MitoQ (MQ) on lipid droplet content and
mitochondrial triglycerides in the hearts of obese rats. Hearts from rats fed a standard diet (CT)
or a high fat diet (HFD) treated with vehicle or with MQ (200 µM) were analyzed. (A) Quantification
of intracellular lipid accumulation and (B) representative microphotographs of sections stained with
DAPI and Oil red O to visualize and quantify nuclei and intracellular lipid droplets, respectively.
(C) Levels of total mitochondrial triglycerides (TGs) and (D) mitochondrial TGs enriched with palmitic
acid (PA; C16:0) are presented. Magnification (×40). Bar graphs represent the mean ± SEM. of 6–8
animals. ** p < 0.01; *** p < 0.001 vs. control group. † p < 0.05; ††† p < 0.001 vs. HFD group.
Total ceramide levels were upregulated in obese rats and were reduced in HFD-treated rats
(Figure 4C). However, the very-long-chain C22:0-ceramide dramatically decreased in obese rats and
normalized with MitoQ treatment (Figure S2C). Total mitochondrial ceramide levels were negatively
associated with those of 18-FDG uptake and positive with the levels of cardiac fibrosis or cardiac
hypertrophy (Table 2).
Considering that there is an accumulation of lipids in the mitochondria of obese animals, we
explored the consequences on proteins involved in different mitochondrial functions. To this end,
we evaluated the levels of two proteins involved in the process of fusion and fission. As shown in
Figure 5A, the protein levels of MFN1 are higher in obese animals as compared with controls. MitoQ
treatment was able to reduce these levels. MFN1 levels were negatively associated with those of
18-FDG uptake and positive with cardiac hypertrophy (Table 2). Neither obesity nor MitoQ were able
to affect the levels of DRP1 (Figure 5B).
Obesity was able to increase Cyclo F levels (Figure 5C), suggesting the opening of the mitochondrial
permeability transition pores (mPTP), which was normalized by MitoQ treatment, supporting the role
of oxidative stress in this process. Also, an increase of PGC1α levels were reduced by MitoQ treatment
(Figure 5D). A reduction in the levels of FH was observed in obese rats, which was normalized by
MitoQ treatment, indicating the participation of mitochondrial ROS in this alteration (Figure 5E). These
levels were negatively correlated with those of cardiac fibrosis and hypertrophy but positive with
those of 18-FDG uptake (Table 2). In addition, FH levels were negatively correlated with those of TG
and ceramides (r = −0.451; p = 0.046, r = −0.485; p = 0.03; respectively). No differences were observed
between HFD and CT animals in the levels of other enzymes involved in citric acid cycle ACS, and
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MitoQ was unable to modify them (Figure S2D). Neither obesity nor MitoQ were able to affect the
levels of cyto C (Figure 5F). We also evaluated the protein levels of the components of mitochondrial
respiratory chain complexes. As shown in Figure 6A–F, obesity exerts a different impact on different
complexes, since obese animals show a decrease in complex I and II but not changes in the levels
of complex III, IV, and V, the ATP synthase. MitoQ treatment was able to prevent these changes
(Figure 6A,B).
Figure 3. Effects of the mitochondrial antioxidant MitoQ (MQ) on protein levels in the hearts of obese
rats. Hearts from rats fed a standard diet (CT) or a high fat diet (HFD) treated with vehicle or with
MQ (200 µM) were analyzed. Protein expression of (A) carnitine palmitoyltransferase 1 (CPT1A),
(B) fatty acid translocase (FAT), (C) diacylglycerol transferase 1 (DAGT1) and (D) adipose triglyceride
lipase (ATL) are presented. Bar graphs represent the mean ± SEM of 6–8 animals normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). * p < 0.05; ** p < 0.01; *** p < 0.001 vs. control
group. † p < 0.05; ††† p < 0.001 vs. HFD group.
Figure 4. Effects the mitochondrial antioxidant MitoQ (MQ) on mitochondrial lipid species in the hearts
from obese rats. Hearts from rats fed a standard diet (CT) or a high fat diet (HFD) treated with vehicle
or with MQ (200 µM) were analyzed. Levels of (A) mitochondrial free fatty acids (FFA), (B) cardiolipins,
and (C) mitochondrial ceramides are presented. Bar graphs represent the mean ± SEM of 6–8 animals
* p < 0.05 vs. control group. † p < 0.05 vs. HFD group.
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Figure 5. Impact of the mitochondrial antioxidant MitoQ (MQ) on mitochondrial protein levels in the
hearts of obese rats. Hearts from rats fed a standard diet (CT) or a high fat diet (HFD) treated with vehicle
or with MQ (200 µM) were analyzed. Protein expression of (A) mitofusin 1 (MFN1), (B) Dynamin-1-like
protein (DRP1), (C) cyclophilin F (Cyclo F), (D) peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1α), (E) fumarate hydratase (FH) and (F) cytochrome C are presented.
Bar graphs represent the mean ± SEM. of 6–8 animals normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). * p < 0.05; ** p < 0.01; *** p < 0.001 vs. control group. † p < 0.05; †† p < 0.01 vs.
HFD group.
Figure 6. Effects of the mitochondrial antioxidant MitoQ (MQ) on mitochondrial complexes protein
levels in the hearts of obese rats. Hearts from rats fed a standard diet (CT) or a high fat diet (HFD) treated
with vehicle or with MQ (200 µM) were analyzed. Protein expression of mitochondrial complexes
(A) I (subunit NDUFB8), (B) II (SDHB subunit of complex II), (C) III (core protein 2 UQCRC2), (D) IV
(MTCO1 subunit 1), and (E) V (alpha subunit) are presented. (F) Representative blots for mitochondrial
complexes protein expressions. Bar graphs represent the mean ± SEM. of 6–8 animals normalized
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). * p < 0.05 vs. control group. † p < 0.05 vs.
HFD group.
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Taking the observed accumulation of PA in the mitochondria into consideration, we decided to
assess whether PA could directly increase oxidative stress or affect mitochondrial proteins involved in
essential functions by using cultured rat cardiomyoblasts. PA induced an increase in mitochondrial
oxidative stress, as suggested by the increase in the levels of 4HNE, a major end-product of lipid
peroxidation (Figure 7A). Similarly, PA induced an increase in CPT1A levels, although it reduced those
of FAT as compared with control conditions (Figure 7B,C, respectively). The presence of MitoQ was
only able to prevent the change in 4HNE and CPT1A levels (Figure 7A–C). An increase in levels of both
Cyclo F and Cyto C were observed in PA-stimulated cells (Figure 7D,E). MitoQ treatment prevented
these changes. No significant changes were observed in response to either PA or MitoQ in the protein
levels of FH, PCG1-α, and MFN1 (Figure 8A–C). Neither PA nor the presence of MitoQ in the medium
was able to affect the expression of the different mitochondrial complexes in H9c2 cells (Figure S3A–F).
Figure 7. Effects of antioxidant MitoQ (MQ) on protein levels in palmitic acid (PA)-treated H9c2 cells.
Protein levels of (A) 4-hydroxynonenal (4HNE), (B) carnitine palmitoyltransferase 1 (CPT1A), (C) fatty
acid translocase (FAT), (D) cyclophilin F (Cyclo F), and (E) cytochrome C in cardiac myoblasts treated
for 24 h with PA (200 µM) in the presence of absence of the mitochondrial antioxidant MitoQ (MQ; 5 nM).
Bar graphs represent the mean ± SEM of four to six assays normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). * p < 0.05; ** p <0.01; *** p <0.001 vs. control conditions. † p < 0.05;
††† p < 0.001 vs. PA-treated cells.
In order to explore the potential pathways involved in the direct actions induced by PA on
mitochondrial proteins in H9c2 cells, we explored its effects on Akt, Erk, and NF-κB phosphorylations
(Figure 8D–G). PA was able to stimulate the phosphorylation of Erk1/2 in cardiac myoblasts, reaching
the maximum level at 10 min, and were elevated until 30 min (Figure 8D). Similarly, PA was able to
phosphorylate NF-κB, reaching the maximum level at 60 min (Figure 8E). However, it was unable to
affect the Akt pathway (Figure 8F).
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Figure 8. Effects of antioxidant MitoQ (MQ) on protein levels in palmitic acid (PA)-treated H9c2
cells. Protein levels of (A) fumarate hydratase (FH), (B) peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α), (C) mitofusin 1 (MFN1) in cardiac myoblasts treated for 24 h
with PA (200 µM) in the presence of absence of the mitochondrial antioxidant MitoQ (MQ; 5 nM). (D)
Phosphorylated protein of extracellular signal-regulated kinases (pErk1/2), (E) phosphorylated protein
of nuclear factor-κB p65 (pNF-κB), and (F) phosphorylated protein kinase B (pAkt) in cardiac myoblasts
treated with PA (200 µM) at different times. (G) Representative images blots for phosphorylation of
intracellular signaling pathways. Bar graphs represent the mean ± SEM of four to six assays normalized
to glyceraldehyde-3-phosphate dehydrogenase (A–C), β-actin, (E) or total Erk1/2 (D) and total Akt (F).
* p < 0.05; ** p < 0.01; *** p < 0.001 vs. control conditions.
4. Discussion
Cardiolipotoxicity, as well as mitochondrial oxidative stress, are well-accepted mechanisms
underlying cardiac damage in the context of obesity. However, the potential interactions between these
mechanisms are a matter of discussion. The results presented here reveal that the increase in total lipids at
the cardiac mitochondrial level observed in obese rats was accompanied by an exacerbation of oxidative
stress, a reduced myocardial glucose uptake, cardiac fibrosis, myocardial hypertrophy and alterations
in the mitochondrial protein in the heart. We postulate that mitochondrial oxidative stress could
participate in cardiac lipotoxicity associated with obesity. Overall, we found that the administration
of the mitochondrial antioxidant MitoQ protects against some of the consequences of diet-induced
obesity, thereby attenuating the disturbances in mitochondrial lipid remodelling, improving cardiac
metabolism, reducing cardiac fibrosis and hypertrophy, and improving the alterations in mitochondrial
proteins observed in obese animals.
HFD-fed animals exhibited a decline in cardiac glucose uptake, suggesting insulin resistance,
a common feature in obese patients [12,18]. This is considered to be an early adaptation to diet-induced
obesity [19] and to trigger an imbalance in cell substrate availability. This metabolic maladaptation
facilitates progressive lipid accumulation. Along these lines, our data show an increase in intracellular
lipid accumulation in the heart. This was accompanied by an increase in mitochondrial TG,
especially those enriched with PA in normotensive obese animals, which supports cardiac lipotoxicity,
a well-established feature in the context of obesity or diabetes [1,2,20]. This excess in TG seems to have
functional consequences because it was associated with cardiac fibrosis and hypertrophy. An increase
in their synthesis could be underlying these high TG levels in obese rats, since the increase in DGAT1
protein levels, the rate-limiting enzyme required for the final step of TG synthesis [21], observed in
obese animals was normalized in those treated with MitoQ that show normal mitochondrial TG levels.
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Similar results have been reported in mice [22,23]. By contrast, a reduction in TG degradation seems
not to play a major role because no differences were observed in ATL, an enzyme involved in the
first step in the intracellular degradation of TG, among any group. This increase in synthesis could
be facilitated by a higher FA uptake at both cellular and mitochondrial levels, since a rise in protein
levels of FAT and CPT1A, respectively, was observed in obese animals. In fact, a correlation was found
between mitochondrial TG levels and those of these proteins. Similar increases have been found and
were associated with high cardiac lipid content, not only in the context of obesity, but also in that of
diabetes and myocardial ischemia [5,16,24].
An increase in FFAs was also observed in obese rats, confirming previous observations, not only
in obesity but also in diabetes [25,26]. This accumulation could involve a higher FA uptake at both
cellular and mitochondrial levels, as mentioned above due to increased lipid supply in obesity. An
increase in lipogenesis or decreased FA oxidation in the cardiomyocytes could not be eliminated. These
high levels are mainly due to saturated andω-6 FFA with a poorer cardiovascular profile. In fact, not
only total levels, but especially theω-6 FFA, and to a lesser degree, saturated ones, were associated
with cardiac fibrosis and cardiac hypertrophy. Similarly, high FFA levels were accompanied by cardiac
hypertrophy and fibrosis, not only in obesity, but in other pathological situations [27,28]. In agreement
with that, different studies have shown that the quality of FA determines shifts to cardiac damage or
cardioprotection [29,30].
Ceramides are not only essential structural components of cell membranes, but also function
as second messenger molecules in cell signaling, and have been implicated in different pathological
settings [31–33]. The present data confirm previous observations, which support a negative effect of
ceramides in insulin signaling in different tissues [16,33,34]. In addition, our data supports a role for
ceramides in myocardial fibrosis, as well as hypertrophy.
Similarly, there have been reported high cardiac levels of both ceramide and collagen in a model
of myocardial infarction in mice [35,36], as well as high ceramide cardiac levels in patients with a
failing heart of a different origin [35]. This increase seems to be mainly due to an increase in novo
formation [35]. The potential role of ceramides in the development of fibrosis could involve the
activation of the transforming growth factor-β signaling pathway [36], which participates in the
development of cardiac fibrosis in diet-induced obesity [37]. In addition, high cardiac ceramide levels
were observed in cardiac hypertrophied hearts, not only in obesity, but also in other pathological
conditions [38,39].
In general, this supports a relevant role of ceramide in the cardiac damage associated with obesity.
In this line, it has been shown that the level of circulating ceramides is a possible biomarker for
identifying patients at risk for major adverse cardiac events [40]. In fact, an association between plasma
ceramides and risk of cardiovascular disease has been reported [41]. Although mitochondrial ceramide
levels were elevated in obese rats overall, the levels of C22:0-ceramide—with protective effect against
hypoxia [42]—were selectively down-regulated in obese rats. Therefore, the imbalance between the
different ceramide species may generate a more harmful cardiac environment in the context of obesity.
Our data also showed that obesity was accompanied by a reduction in total cardiac CL levels,
confirming previous findings not only in the context of obesity, but also in other pathological conditions,
including diabetes, heart failure, and myocardial ischemia [5,43,44]. This decrease can occur even
before TG accumulation [45] and could be a consequence of a reduction in CL synthesis [46]. These
lower CL levels were associated with cardiac fibrosis, supporting functional consequences. CL are
essential components of mitochondrial membrane that interacts with membrane proteins involved
in mitochondrial functions, including some which regulate bioenergetics, membrane structure, and
apoptosis [47–49]. In this regard, we found a reduction in complexes I and III protein levels, supporting
the notion of an impaired oxidative phosphorylation that further supports an impaired energy balance.
Also involved in such impairment is a reduction in FH, an enzyme involved in tricarboxylic acid cycle,
observed in the hearts of obese animals.
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Obese rats showed higher PCG-1α levels than CT animals, supporting an increase in mitochondrial
biogenesis. Similarly, obesity was accompanied by higher protein levels of MFN1, thereby suggesting
an augmented fusion that adapts the morphology of the mitochondria to the metabolic needs of the
cell. These changes could be an adaptation to energy stress, since maintaining mitochondrial mass, or
even an enhancement after reduced energy source, permits mitochondria to maximize the cell energy
supply [50].
An exacerbation of oxidative stress, mainly from mitochondrial origin, is linked to mitochondrial
lipid remodeling and, in consequence, the cardiac damage associated with obesity, since the
administration of MitoQ was able to normalize the cardiolipotoxicity, mitochondrial alterations
and the cardiac consequences of obesity. A role of oxidative stress has also been reported in the cardiac
damage associated, not only with obesity, but also with aging, heart failure and hypertension [10,51,52].
In this regard, myocardial ischemia-reperfusion was accompanied by changes in cardiac metabolism in
a model of non-obese and non-diabetic mice with ectopic lipid deposition, leading to severe myocardial
dysfunction. These alterations were associated with cardiac mitochondrial alterations and increased
ROS production, suggesting the possible role of mitochondrial oxidative stress in these alterations [53].
Mitochondria are the main source of intracellular ROS production, which occurs through electron
leakage as a byproduct of ATP generation by oxidative phosphorylation. In addition, the reduced
levels of FH can also participate in the increases of fumarate concentration and promote oxidative stress
in cardiac cells [54]. The increased oxidative stress can also stimulate the appearance of permeability
transition pore (mPTP), an opening that contributes to mitochondrial dysfunction, since it has been
shown that the upregulation of cycloF occurs in a ROS-dependent manner [55]. The cycloF induces
the opening of mPTP, leading to osmotic imbalance and consequent mitochondrial swelling, which
triggers cell death. In addition, further cardiac actions have been proposed for cycloF, including cardiac
hypertrophy and fibrosis [56,57].
Our data show that mitochondrial oxidative stress is involved in the consequences of
cardiolipotoxicity in the context of obesity by facilitating the lipid remodeling and, therefore, the cardiac
consequences observed in obese rats. Moreover, the data show that PA, the main FA accumulated in
the heart of obese rats, is able to stimulate oxidative stress in H9C2 cells and facilitates some of the
alterations observed in the heart of obese rats, thereby closing a vicious circle. The presence of PA
increased the protein levels of CPT1A, supporting the notion of a higher FA uptake at mitochondrial
levels, although a reduction in those of FAT could be a compensatory mechanism to excess exposure
to FFAs. PA also induced the appearance of mPTP, as suggested by the increase in cyclopF protein
levels. Such an increase was accompanied by a rise in Cyto C levels, a fact previously reported in
H9c2 cells in response to PA [58]. However, we did not evaluate where these high levels were located,
although they could be expected to be cytoplasm since it can escape through mPTP, thereby reducing
mitochondrial levels [58]. MitoQ ameliorated the increase in CPT1A, CycloF, and Cyto C induced
by PA in these cells, in agreement with our in vivo data. It has consistently been reported that PA
interferes with several signaling pathways, including the Erk and NF-κB pathways [58,59]. Therefore,
these data suggest interactions between lipotoxicity and mitochondrial oxidative stress, which regulate
downstream events responsible for cardiac alterations in the context of obesity.
The direct exposition of H9C2 cells to PA was unable to affect other mitochondrial proteins
involved in relevant functions that were affected in obese rats, including MFN1, PGC1α, or FH.
A similar situation was found with the mitochondrial complexes, supporting that factor or factors
activated by the complex environment that occurs in the context of obesity could be necessary to affect
these mitochondrial proteins.
In summary, to understand the interactions among the mechanisms that underlie the cardiac
damage in the context of obesity is crucial. Our present data show the cardiac alterations observed
in obese rats were accompanied by an important remodeling in the mitochondrial lipids that can be
facilitated by the excess of mitochondrial oxidative stress. In addition, PA was able to stimulate oxidative
stress in cardiac myoblasts and altered some of the proteins involved in essential functions of the
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mitochondria observed in the obese animals. Therefore, the data suggest a crosstalk between lipotoxicity
and mitochondrial oxidative stress, drawing a more complex scenario of the role of mitochondria
in cardiac damage in the context of obesity and suggest new approaches in the management of
obesity-related heart damage.
Supplementary Materials: The following figures are available online at http://www.mdpi.com/2073-4409/9/2/451/s1,
Figure S1: Effects of the mitochondrial antioxidant MitoQ (MQ) on mitochondrial superoxide anion levels.
Figure S2. Impact of the mitochondrial antioxidant MiToQ on mitochondrial lipid species and protein levels in
heart of obese rats. Figure S3. Effects of antioxidant MiToQ on complexes protein levels in palmitic-acid-treated
H9c2 cells.
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